Background: Fatigue is a common, persistent complaint following traumatic brain injury (TBI). Effective treatment is not well established.
Objective: .The current study aimed to investigate the efficacy of 4 weeks of light therapy for fatigue in patients with TBI.
Methods: We undertook a randomized, placebo-controlled study of 4-week, 45 min/morning, home-based treatment with short wavelength (blue) light therapy (λmax = 465 nm, 84.8 µW/cm(2), 39.5 lux, 1.74 × 10(14) photons/cm(2)/s) compared with yellow light therapy (λmax = 574 nm, 18.5 µW/cm(2), 68 lux, 1.21 × 10(12) photons/cm(2)/s) containing less photons in the short wavelength range and a no treatment control group (n = 10 per group) in patients with TBI who self-reported fatigue and/or sleep disturbance. Assessments of fatigue and secondary outcomes (self-reported daytime sleepiness, depression, sleep quality, and sustained attention) were conducted over 10 weeks at baseline (week -2), midway through and at the end of light therapy (weeks 2 and 4), and 4 weeks following cessation of light therapy (week 8).
Results: After controlling age, gender, and baseline depression, treatment with high-intensity blue light therapy resulted in reduced fatigue and daytime sleepiness during the treatment phase, with evidence of a trend toward baseline levels 4 weeks after treatment cessation. These changes were not observed with lower-intensity yellow light therapy or no treatment control conditions. There was also no significant treatment effect observed for self-reported depression or psychomotor vigilance performance.
Conclusions: Blue light therapy appears to be effective in alleviating fatigue and daytime sleepiness following TBI and may offer a noninvasive, safe, and nonpharmacological alternative to current treatments.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/1545968313508472 | DOI Listing |
Adv Sci (Weinh)
January 2025
The Department of Medical Imaging, The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Xingangzhong Road 466, Guangzhou, 518037, P. R. China.
Photodynamic therapy (PDT) and photothermal therapy (PTT) have emerged as promising treatment options, showcasing immense potential in addressing both oncologic and nononcologic diseases. Single-component organic phototherapeutic agents (SCOPAs) offer advantages compared to inorganic or multicomponent nanomedicine, including better biosafety, lower toxicity, simpler synthesis, and enhanced reproducibility. Nonetheless, how to further improve the therapeutic effectiveness of SCOPAs remains a challenging research area.
View Article and Find Full Text PDFChem Biol Drug Des
January 2025
Cardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Hepatocellular carcinoma (HCC) presents an escalating public health challenge globally. However, drug resistance has emerged as a major impediment to successful HCC treatment, limiting the efficacy of curative interventions. Despite numerous investigations into the diverse impacts of hsa-miR-125a-5p on tumor growth across different cancer types, its specific involvement in chemotherapy resistance in HCC remains elusive.
View Article and Find Full Text PDFAdv Skin Wound Care
January 2025
Meryem Aydin, PhD, is Assistant Professor, Faculty of Health Science, Department of Pediatric Nursing, Duzce University, Konuralp, Düzce, Turkey. Serap Balci, PhD, is Associate Professor, Florence Nightingale Nursing Faculty, Department of Pediatric Nursing, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
Objective: To compare transepidermal water loss (TEWL) in preterm newborns treated with two different types of phototherapies.
Methods: In this experimental randomized controlled study, participants were 60 preterm infants aged 30 to 36 weeks' gestation who were admitted to the neonatal ICU of Duzce University Research and Application Center from December 2015 to May 2016. Researchers randomly assigned the newborns to two phototherapy groups: light-emitting diode (LED) and fluorescent phototherapy.
Am J Ther
January 2025
Faculty of Medicine, Transilvania University of Brasov, Brasov, Romania.
Background: The management of bipolar disorder during pregnancy presents a significant challenge, particularly regarding the safety and effectiveness of long-acting injectable (LAI) antipsychotics like aripiprazole. Despite the growing use of LAI antipsychotics in psychiatric disorders, data on their use during pregnancy are limited, especially for bipolar disorder. This study aimed to shed light on this issue through a scoping review.
View Article and Find Full Text PDFPhotodermatol Photoimmunol Photomed
January 2025
Hospital Universitario Clínico San Cecilio, Granada, Spain.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!